Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.39B Sell
9,509,991
-1,605,168
-14% -$345M 0.57% 30
2026
Q1
$2.42B Buy
11,115,159
+2,507,133
+29% +$556M 0.65% 19
2025
Q4
$1.97B Buy
8,608,026
+524,495
+6% +$119M 0.52% 21
2025
Q3
$1.87B Sell
8,083,531
-273,743
-3% -$55.7M 0.49% 25
2025
Q2
$1.55B Sell
8,357,274
-325,208
-4% -$60.4M 0.43% 34
2025
Q1
$1.82B Sell
8,682,482
-405,872
-4% -$78.9M 0.55% 27
2024
Q4
$1.62B Sell
9,088,354
-421,017
-4% -$77.4M 0.46% 31
2024
Q3
$1.88B Sell
9,509,371
-101,096
-1% -$18.9M 0.53% 26
2024
Q2
$1.65B Buy
9,610,467
+723,838
+8% +$120M 0.48% 29
2024
Q1
$1.62B Sell
8,886,629
-220,600
-2% -$38M 0.48% 29
2023
Q4
$1.41B Sell
9,107,229
-1,345,476
-13% -$196M 0.45% 38
2023
Q3
$1.56B Sell
10,452,705
-495,010
-5% -$72.7M 0.55% 27
2023
Q2
$1.47B Sell
10,947,715
-428,384
-4% -$62.8M 0.51% 30
2023
Q1
$1.81B Sell
11,376,099
-977,479
-8% -$149M 0.67% 21
2022
Q4
$2B Sell
12,353,578
-1,212,368
-9% -$186M 0.77% 14
2022
Q3
$1.82B Sell
13,565,946
-1,124,828
-8% -$161M 0.74% 16
2022
Q2
$2.25B Sell
14,690,774
-1,701,065
-10% -$260M 0.87% 13
2022
Q1
$2.62B Buy
16,391,839
+60,090
+0.4% +$8.73M 0.85% 15
2021
Q4
$2.21B Buy
16,331,749
+1,727,890
+12% +$204M 0.65% 21
2021
Q3
$1.58B Sell
14,603,859
-704,102
-5% -$80.5M 0.49% 34
2021
Q2
$1.72B Sell
15,307,961
-2,007,205
-12% -$226M 0.51% 26
2021
Q1
$1.87B Buy
17,315,166
+19,506
+0.1% +$2.09M 0.6% 25
2020
Q4
$1.85B Sell
17,295,660
-2,817,162
-14% -$271M 0.63% 22
2020
Q3
$1.76B Sell
20,112,822
-2,011,667
-9% -$189M 0.68% 20
2020
Q2
$2.17B Buy
22,124,489
+6,956,787
+46% +$613M 0.88% 12
2020
Q1
$1.16B Buy
15,167,702
+2,126,043
+16% +$181M 0.56% 32
2019
Q4
$1.15B Buy
13,041,659
+2,592,492
+25% +$215M 0.44% 42
2019
Q3
$791M Buy
10,449,167
+855,322
+9% +$58.6M 0.32% 61
2019
Q2
$698M Buy
9,593,845
+9,065,487
+1,716% +$713M 0.27% 72
2019
Q1
$42.6M Sell
528,358
-31,240
-6% -$2.56M 0.23% 95
2018
Q4
$51.6M Buy
559,598
+173,898
+45% +$15.3M 0.33% 56
2018
Q3
$36.5M Buy
385,700
+115,585
+43% +$11M 0.19% 142
2018
Q2
$25M Buy
270,115
+5,236
+2% +$511K 0.16% 198
2018
Q1
$25.1M Sell
264,879
-314,312
-54% -$34.5M 0.16% 190
2017
Q4
$56M Sell
579,191
-79,796
-12% -$7.52M 0.36% 57
2017
Q3
$58.6M Buy
658,987
+69,530
+12% +$5.29M 0.38% 56
2017
Q2
$42.7M Sell
589,457
-12,588
-2% -$846K 0.27% 84
2017
Q1
$39.2M Sell
602,045
-101,635
-14% -$6.39M 0.23% 102
2016
Q4
$44.1M Buy
703,680
+161,967
+30% +$9.89M 0.22% 109
2016
Q3
$34.2M Buy
541,713
+10,773
+2% +$697K 0.2% 117
2016
Q2
$32.9M Sell
530,940
-86,772
-14% -$5.29M 0.2% 121
2016
Q1
$35.3K Sell
617,712
-86,413
-12% -$4.82M 0.18% 112
2015
Q4
$41.7K Sell
704,125
-21,119
-3% -$1.22M 0.21% 92
2015
Q3
$39.5K Sell
725,244
-27,206
-4% -$1.77M 0.22% 102
2015
Q2
$50.6K Sell
752,450
-721
-0.1% -$47.1K 0.27% 82
2015
Q1
$44.1M Buy
753,171
+337,177
+81% +$20.4M 0.24% 104
2014
Q4
$27.2M Buy
415,994
+27,403
+7% +$1.73M 0.15% 184
2014
Q3
$22.4M Buy
388,591
+259,251
+200% +$14.4M 0.14% 199
2014
Q2
$7.3M Sell
129,340
-15,967
-11% -$838K 0.04% 444
2014
Q1
$7.47M Sell
145,307
-9,108
-6% -$460K 0.04% 421
2013
Q4
$8.15M Sell
154,415
-15,456
-9% -$760K 0.05% 408
2013
Q3
$7.6M Sell
169,871
-3,670
-2% -$163K 0.05% 427
2013
Q2
$7.17M Buy
+173,541
New +$7.59M 0.05% 426

Other funds holding ABBV

Nuveen's ABBV Position: Q2 2026 in Review

Nuveen reduced its AbbVie (ABBV) stake by 14% in Q2 2026, selling an estimated $345M and leaving 9,509,991 shares worth $2.39B. The position accounts for 0.57% of the portfolio, ranked #30.

Nuveen first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.62B in Q1 2022. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Nuveen held 9,509,991 shares of AbbVie worth $2.39B as of Q2 2026.
  • Nuveen sold 1,605,168 AbbVie shares in Q2 2026, an estimated $345M.
  • AbbVie made up 0.57% of Nuveen's portfolio in Q2 2026, its #30 holding.
  • Nuveen first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Nuveen's AbbVie position peaked at $2.62B in Q1 2022.
  • 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.